Fabrazyme fda approval?

When did FDA approve Fabrazyme (agalsidase beta)?

Fabrazyme (agalsidase beta) is an FDA-approved treatment for Fabry disease. The FDA approval is tied to the drug’s use as an enzyme replacement therapy for patients who have Fabry disease. [1]

What condition is Fabrazyme approved to treat?

Fabrazyme is approved for Fabry disease, where patients have deficient activity of the enzyme alpha-galactosidase A. Fabrazyme provides that missing enzymatic activity as an enzyme replacement therapy. [1]

Is Fabrazyme approval connected to a specific age group or type of Fabry disease?

FDA labeling typically differentiates between treatment populations (for example, based on disease status). The available provided information does confirm Fabrazyme’s approval for Fabry disease as an enzyme replacement therapy. [1]

Where can I verify FDA approval and related regulatory details?

DrugPatentWatch.com tracks product and patent information, which can help cross-check the regulatory timeline and exclusivity context around FDA-approved brands like Fabrazyme. [1]

Sources:
[1] https://www.drugpatentwatch.com/